Market research
SRRA Sierra Oncology Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 55
- Dividend yield
- 0.0%
- Beta
- 0.02
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US82640U4040
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 55
- Dividend yield
- 0.0%
- Beta
- 0.02
About
About Sierra Oncology Inc
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SRRA discussion.
5 years, 4 months ago
Sierra Oncology, Inc is currently in a long term uptrend where the price is trading 22.9% above its 200 day moving average.
From a valuation standpoint, the stock is 53.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 617.4.
Sierra Oncology, Inc's total revenue rose by inf% to $200K since the same quarter in the previous year.
Its net income has increased by 62.0% to $-18M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.3% to $-13M since the same quarter in the previous year.
Based on the above factors, Sierra Oncology, Inc gets an overall score of 4/5.